What is Prandin (Repaglinide) Used For? Side Effects and Dosage
What is Prandin (repaglinide)?
Prandin is an oral tablet containing the blood-glucose lowering drug repaglinide. It’s used to maintain glucose control in patients with type 2 diabetes mellitus.
Prandin is recommended for patients whose hyperglycemia cannot be effectively controlled by diet and exercise alone. It’s also indicated for combination therapy with metformin when that drug alone does not achieve sufficient glycemic control.
Prandin can also be used in combination with rosiglitazone in patients for whom metformin is contraindicated. Patients taking Prandin should not take gemfibrozil and repaglinide at the same time. This medication should also be avoided if patients are taking clopidogrel and repaglinide simultaneously as there are serious contraindications with these dosing regimens.
The repaglinide drug class is known as meglitinides. Prandin is manufactured by Novo Nordisk and has been approved by the Food and Drug Administration (FDA) since 1997.
What is this medication used for?
Prandin is used to control blood sugar levels in people with type 2 diabetes. It should be used in conjunction with a good diet and plenty of exercise. Cardiovascular risk factors should be established before starting treatment with Prandin.
How to take
Prandin is taken as a tablet before mealtimes. There is no fixed dosage regimen for the drug, therefore patients who are considering treatment should consult closely with a physician to develop a suitable dosing schedule.
The drug should be administered 15 minutes before a meal, but patients may take it immediately before eating or up to 30 minutes beforehand.
Prandin side effects
The most commonly reported side effect of Prandin is hypoglycemia. If a patient becomes hypoglycemic during therapy, aggressive treatment with oral glucose and subsequent monitoring by a clinician is recommended.
This medication is generally well-tolerated. The most common secondary side effects are gastrointestinal. There was a small but clinically significant increase in serious cardiovascular events for those taking Prandin relative to control patients.
Common side effects
Severe side effects
- Cardiovascular effects
Prandin is available in tablets containing 0.5 mg, 1 mg, or 2 mg of the active ingredient. For patients beginning Prandin therapy who have not been previously treated with anti-diabetic agents, or who have an HbA1c of <8%, the usual initiation dose is 0.5 mg, preprandially, for each meal.
For patients who have previously been treated with drugs to lower blood glucose, or if the patient’s HbA1c is ≥8%, the initial preprandial dose for each meal is usually 1 mg or 2 mg. Dosage adjustments should be made based on blood glucose response, generally measured by fasting blood glucose analysis. The preprandial dosage can be titrated up to 4 mg of Prandin until a satisfactory reduction in blood glucose levels have been achieved.
The drug generic options
A Prandin generic is manufactured by Mylan and sold as Repaglinide.
Disclaimer: Please note that the contents of this community article are strictly for informational purposes and should not be considered as medical advice. This article, and other community articles, are not written or reviewed for medical validity by Canadian Insulin or its staff. All views and opinions expressed by the contributing authors are not endorsed by Canadian Insulin. Always consult a medical professional for medical advice, diagnosis, and treatment.